DeckTherapeutics
Private Company
Funding information not available
Overview
DeckTherapeutics is a private, preclinical-stage biotech based in Cambridge, USA, founded in 2021. The company is developing THDG3, a proprietary intravenous omega-3 fatty acid emulsion, as a neuroprotectant for acute brain injuries caused by oxygen deprivation. Its lead indication is neonatal hypoxic-ischemic encephalopathy (HIE), with ischemic stroke as a secondary target, addressing significant unmet medical needs where no neuroprotectants are currently approved. The technology platform originated from research at Columbia University.
Technology Platform
Proprietary platform for acute intravenous omega-3 fatty acid therapeutics, featuring semi-synthetic omega-3 fatty acid glyceride emulsions that exert pleiotropic effects to inhibit cellular apoptosis and necrosis following hypoxic-ischemic injury.
Opportunities
Risk Factors
Competitive Landscape
The neuroprotection space is crowded with historical failures and no approved drugs, but remains active with companies pursuing various mechanisms. For neonatal HIE, therapeutic hypothermia is the standard of care, creating a high bar for an adjunctive drug. In stroke, competition is intense from both reperfusion therapies and other investigational neuroprotectants.